a small trial of a new experimental rectal cancer drug had results that are “unheard of” in the world of cancer treatment: every single patient saw their tumours disappear.
“i don’t think anyone has seen this before, where every single patient has had the tumour disappear,” the study’s lead author dr. andrea cercek, an oncologist with memorial sloan kettering cancer center in new york,
told the washington post
.
another co-author, dr. luis diaz,
told the new york times
he believes “this is the first time this has happened in the history of cancer.”
nine doses of the drug, dostarlimab, was given intravenously to 14 patients with early-stage rectal cancer. it works as a “checkpoint inhibitor,”
the guardian explains
: it works to remove a shield-like protectant that cancer cells build around the tumour. with that shield removed, the cancer cells can be identified and destroyed by the body’s immune system.
after six months of treatment, the tumours were gone in every patient. not one of them had cancer cells that could be detected by biopsies, scans or other exams.
“all 14 patients? the odds are exceedingly low and really unheard of in oncology,” cercek told the washington post.
of course, 14 is a relatively low sample size. these 14 patients were all in early stages of their cancer, and the good results are still recent — tumours could potentially re-emerge later on. also, the patients also have another very specific factor in common: their tumours all had a specific mutation — mismatch repair-deficiency — which means that the dna repair system in their cells does not function normally.